You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(02607.HK)上半年歸母淨利達36.96億元 同比增長3.58%
格隆匯 08-29 18:02

格隆匯8月29日丨上海醫藥(02607.HK)公佈,2022年1-6月,公司實現營業收入1,117.07億元(幣種為人民幣,下同),同比增長6.15%;其中醫藥工業實現收入130.50億元,同比增長3.56%;醫藥商業實現收入986.57億元,同比增長6.50%。

公司實現歸屬於上市公司股東的淨利潤36.96億元,同比增長3.58%。其中醫藥工業主營業務貢獻利潤11.04億元,同口徑下降4.87%;醫藥商業主營業務貢獻利潤17.45億元,同比增長30.95%;主要聯合營企業貢獻利潤3.35億元,同比下降42.89%。實現扣除非經常性損益的歸屬於上市公司股東淨利潤26.81億元,同比增長5.09%。扣除參股企業投資收益,上半年扣除非經常性損益後的歸母淨利潤同比增長18.66%。

報吿期內,公司綜合毛利率13.12%,較上年同期增長0.11個百分點,其中醫藥工業毛利率57.84%,醫藥分銷毛利率6.87%

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account